Using FDG-PET to Guide Hodgkin Lymphoma Treatment

News
Video
Conference|American Society of Hematology Annual Meeting & Exposition (ASH)

This interview examines the role of functional imaging to direct therapy (escalation or de-escalation) for early and advanced Hodgkin lymphoma.

In this interview, Peter Johnson, MD, of the University of Southampton in the United Kingdom, discusses the results of trials testing the role of FDG–positron emission tomography (PET) to direct therapy (escalation or de-escalation) for patients with both early and advanced Hodgkin lymphoma.

Dr. Johnson spoke at an education session on how Hodgkin lymphoma is treated today and the challenges ahead at the 58th Annual Meeting of the American Society of Hematology, held December 3–6 in San Diego, California.

Recent Videos
Pallawi Torka, MD, with the Oncology Brothers presenting slides
Pallawi Torka, MD, with the Oncology Brothers presenting slides
Pallawi Torka, MD, with the Oncology Brothers presenting slides
Pallawi Torka, MD, with the Oncology Brothers presenting slides
Carla Casulo, MD, with the Oncology Brothers presenting slides
Carla Casulo, MD, with the Oncology Brothers presenting slides
Carla Casulo, MD, with the Oncology Brothers presenting slides
Carla Casulo, MD, with the Oncology Brothers presenting slides
Carla Casulo, MD, with the Oncology Brothers presenting slides
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
Related Content
The FDA has set a Prescription Drug User Fee Act date in the first quarter of 2025 for the potential approval of acalabrutinib in previously untreated MCL.

Acalabrutinib Earns FDA Priority Review in Untreated Mantle Cell Lymphoma

Russ Conroy
October 3rd 2024
Article

The FDA has set a Prescription Drug User Fee Act date in the first quarter of 2025 for the potential approval of acalabrutinib in previously untreated MCL.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

Rahul Banerjee, MD, FACP;Noopur Raje, MD
September 2nd 2024
Podcast

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Reconsidering REMS Mandate May Improve CAR T-Cell Therapy Accessibility

Reconsidering REMS Mandate May Improve CAR T-Cell Therapy Accessibility

ONCOLOGY Staff
September 23rd 2024
Article

Nausheen Ahmed, MD, discusses the FDA REMS mandate to help assess toxicity in patients receiving CAR T-cell therapy.

Nausheen Ahmed, MD, discusses findings from a study supporting reduced monitoring windows for patients with lymphoma who receive CAR T-cell therapy.

Improving CAR T-Cell Therapy Monitoring Strategies and Access in Lymphoma

Nausheen Ahmed, MD
July 29th 2024
Podcast

Nausheen Ahmed, MD, discusses findings from a study supporting reduced monitoring windows for patients with lymphoma who receive CAR T-cell therapy.

Treatment with valemetostat yields responses across all PTCL subtypes in the phase 2 VALENTINE-PTCL01 trial.

Valemetostat Shows Meaningful Benefit in Peripheral T-Cell Lymphoma

Chris Ryan
September 10th 2024
Article

Treatment with valemetostat yields responses across all PTCL subtypes in the phase 2 VALENTINE-PTCL01 trial.

Data from the IMerge trial affirm the enduring responses and clinical benefit with imetelstat in those with transfusion-dependent MDS.

Lower-Risk MDS Population Has Enduring RBC-TI Following Imetelstat Therapy

Ashling Wahner
September 8th 2024
Article

Data from the IMerge trial affirm the enduring responses and clinical benefit with imetelstat in those with transfusion-dependent MDS.